The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells

Leukemia

Volumn 23, Issue 4, 2009, Pages 679-685

  Belloc, F ^a,b   Airiau, K ^a,b   Jeanneteau, M ^a,b   Garcia, M ^a,b   Guerin E ^a,b   Lippert, E ^a,b   Moreau Gaudry, F ^a,b   Mahon, F X ^a,b  

^a INSERM   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CELL ANTIBODY; IMATINIB; NILOTINIB; SHORT HAIRPIN RNA; STEM CELL FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL STRAIN K 562; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 64849091009     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.364     Document Type: Article

References (27)

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
2. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
3. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-3475.
4. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109 4016-4019.
5. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998; 16: 1383-1390.
6. de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L. STAT5-dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000; 3: 299-305.
7. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000; 191: 977-984.
8. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): Evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-3311.
9. Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K et al Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 2004; 24: 6172-6183.
10. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: Role of BCR/ ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005; 65: 9436-9444.
11. Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F et al. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther 2007; 6: 912-919.
12. Inaba T. Cytokine-mediated cell survival. Int J Hematol 2004; 80: 210-214.
13. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
14. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800.
15. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006; 66: 10959-10966.
16. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y et al. A common signaling cascade may underlie 'addiction' to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006; 10: 425-435.
17. Carrion RP, Gracian AC, Hernandez PS. Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2007; 8: 425-428.
18. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111: 2329-2338.
19. Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748-755.
20. Belloc F, Cotteret S, Labroille G, Schmit V, Jaloustre C, Dumain P et al. Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines. Cell Death Differ 1997; 4: 806-814.
21. Vayssiere JL, Petit PX, Risler Y, Mignotte B. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc Natl Acad Sci USA 1994; 91: 11752-11756.
22. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539.
23. Martin-Henao GA, Ingles-Esteve J, Cancelas JA, Garcia J. Isolation of CD34+ hematopoietic progenitor cells in chronic myeloid leukemia by magnetic activated cell sorting (MACS). Bone Marrow Transplant 1996; 18: 603-609.
24. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C et al High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55-60.
25. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108: 1328-1333.
26. Tojyo A, Miyazaki Y, Usui N, Kobyashi Y, Okamoto S, Oyashiki K et al Phase I study of nilotinib in patients (pts) from Japan with imatinib-resistant Ph+ chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL). J Clin Oncol (Meet Abstr) 2007; 25 (suppl): 17511.
27. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.